Sequitur and Intradigm collaborate on RNAi
Intradigm, based in Natick. MA, and Sequitur, from Rockville, MD, have agreed to collaborate on the application of RNAi in animal model studies of disease and the development of RNAi therapeutics.
Intradigm, based in Natick. MA, and Sequitur, from Rockville, MD, have agreed to collaborate on the application of RNAi in animal model studies of disease and the development of RNAi therapeutics.
RNAi is a form of double stranded RNA that can be employed to specifically inhibit the expressi of disease causing genes. Sequitur will provide and licence its Stealth RNAi technology to Intradigm for a number of therapeutic targets, while Intradigm will provide and licence its TSGV in vivo nucleic acid delivery technology to sequitur for a number of therapeutic targets.
Tod Woolf, sequitur's ceo commented: 'We believe our Stealth RNAi compounds, and Intradigm's proven nucleic acid delivery system constitutes one of the most advanced therapeutic RNAi development programmes.'
John Spears, ceo of Intradigm, said: 'WE are very pleased to be combining their RNAi technology, with our delivery technology, with the goal of developing this new, exciting, class of potential therapeutics.'